Academia Sinica

Han-Yi Huang

Che Ma

Kuo-I Lin

Chi-Huey Wong

Szu-Wen Wang

Xiaorui Chen

Yi-Hsuan Chang

The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

Coronavirus vaccine

The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

Antibody specific to spike protein of SARS-CoV-2 and uses thereof

Growing community of inventors

Taoyuan, Taiwan

Han-Yi Huang